Original Research

The benefits of a standardized approach to opioid prescribing

Author and Disclosure Information

 

References

We noted that some patients elected to begin a new, nonopioid medication intended to augment their pain relief. However, they did not decrease their use of opioid medicines. We did not collect pain rating scale scores to determine whether the addition of augmenting medicines provided a reduction in pain perception.

Close monitoring of COT patients with frequent office visits may have had an impact on their care. We noted an association between more frequent visits and initiation of pain augmentation medicines. There was also a nonsignificant trend between office visit frequency and dose reduction. These are topics we may re-examine in our practice over time. There was no change in office visit frequency with our intervention, likely a result of these patients having frequent office visits for multiple comorbid medical conditions at baseline.

Evidence of similar benefits in primary care practices that standardized their opioid prescribing guidelines for patients on COT11 illustrates the importance of such a process for ensuring patient safety and decreasing opioid dosage and use.

Limitations to our project are that we did not measure functional changes and quality-of-life scores for patients. We also did not note the opioid dosages for individuals who chose to stop using opioids.

Looking forward. Based on our experience, patient notification with discussion of COT risks, benefits, and alternatives, as well as implementation of a process to monitor COT, appear to be related to patients’ decisions to discontinue COT. Our new standard process did show QI in the process steps but remained suboptimal to our expectations of clinical impact. More frequent office visits may impact patient decisions to reduce opioid dose and to add an augmenting pain medication. We plan to increase the involvement and responsibilities of our allied health staff in our processes to improve rates of adherence and the overall quality of how we manage patients on chronic opioid therapy.

CORRESPONDENCE
David Patchett, DO, Mayo Clinic, 13400 East Shea Blvd, Scottsdale, AZ 85259; patchett.david@mayo.edu

Pages

Recommended Reading

Treatment in prison systems might lead to drop in overdose deaths
MDedge Family Medicine
Mindfulness-based relapse prevention tied to lower anxiety, depression
MDedge Family Medicine
CBT intervention tied to Internet addiction remission in men
MDedge Family Medicine
Opioid exposure leads to poor perinatal and postnatal outcomes
MDedge Family Medicine
Medicare going in ‘right direction’ on opioid epidemic
MDedge Family Medicine
Vaping device marketers take aim at youth through social media
MDedge Family Medicine
Drug overdose deaths declined in 2018
MDedge Family Medicine
Smoking-cessation attempts changed little over 7-year span
MDedge Family Medicine
Pharmacist stigma a barrier to rural buprenorphine access
MDedge Family Medicine
Fetal alcohol exposure overlooked again?
MDedge Family Medicine